We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ABSSSI

News List

US FDA accepts the NDA for Motif Bio’s iclaprim for ABSSSI treatment pharmaceutical-technology
August 17, 2018
The US Food & Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) by Motif Bio for iclaprim, which is a targeted, Gram-positive investigational antibiotic, indicated for the treatment of acute bacterial skin and skin struct
Motif Bio’s antibiotic granted US priority review pharmatimes
August 15, 2018
US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Cardiome Pharma’s Xydalba treatment for ABSSSI available in UK pharmaceutical-technology
June 27, 2017
Canadian pharmaceutical company Cardiome Pharma’s new intravenous (IV) antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, known as Xydalba (dalbavancin hydrochloride), has been made available in the UK.